Takeda Pharmaceutical Co Ltd
TSE:4502
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
JP |
Takeda Pharmaceutical Co Ltd
TSE:4502
|
6.5T JPY | 14.3 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 438.2 | |
US |
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | 177.5 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 36.5 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 930.6 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 4 251.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 16.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 27.1 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
188.8B GBP | 194.6 | ||
CH |
Novartis AG
SIX:NOVN
|
181.8B CHF | 14.1 | ||
CH |
Roche Holding AG
SIX:ROG
|
174.4B CHF | 11.8 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.